Everything below concerns ACTH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
The figure shows the main components of an APPI source: a nebulizer probe which can be heated to 350–500 °C, an ionization region with a VUV photon source, and an ion-transfer region under intermediate pressure that introduces ions into the MS analyzer. The analyte(s) in solution from the HPLC flows into the nebulizer at a flow rate that can range from μL/min to mL/min range. The liquid flow is vaporized by nebulization and heat. The vaporized sample then enters into the radiation zone of the VUV source. Sample ions then enter into the MS interface region, frequently a capillary through the combination of a decreasing pressure gradient and electric fields. APPI has been commercially developed as dual ionization sources more commonly with APCI, but also with ESI.
== Drug interactions == A significant interaction has also been recorded with allopurinol, and administration of these drugs together should be avoided. Reduction in indinavir and delavirdine plasma levels have been shown to occur when administered simultaneously with didanosine; these drugs should be administered at different times. Ketoconazole, itraconazole, ciprofloxacin should be administered at a different time from didanosine due to interactions with the buffering agent. Administration with drugs with overlapping toxicity, such as zalcitabine and stavudine, is not recommended. Alcohol can exacerbate didanosine's toxicity, and avoiding drinking alcohol while taking didanosine is recommended.
Meitnerium is a synthetic chemical element; it has symbol Mt and atomic number 109. It is an extremely radioactive synthetic element (not naturally occurring, but can be created in a laboratory). The most stable known isotope, meitnerium-278, has a half-life of 4.5 seconds, although the unconfirmed meitnerium-282 may have a longer half-life of 67 seconds. The element was first synthesized in August 1982 by the GSI Helmholtz Centre for Heavy Ion Research near Darmstadt, Germany, and it was named after the Austrian-Swedish nuclear physicist Lise Meitner in 1997. In the periodic table, meitnerium is a d-block transactinide element. It is a member of the 7th period and is placed in the group 9 elements, although no chemical experiments have yet been carried out to confirm that it behaves as the heavier homologue to iridium in group 9 as the seventh member of the 6d series of transition metals. Meitnerium is calculated to have properties similar to its lighter homologues, cobalt, rhodium, and iridium.
Insulin as a medication is sold under many different trade names, which are listed below. A dagger symbol (†) indicates discontinued brands. Different brands of insulin may offer any of the following preparation methods: vials, pens, cartridges, IV bags or inhalers. All insulin analogues and non-analogue insulins work by enhancing glucose uptake in tissues and reducing glucose production by the liver. Insulin is prescribed for conditions such as type 1 diabetes, type 2 diabetes, gestational diabetes, and diabetes-related complications such as diabetic ketoacidosis. Additionally, insulin is administered alongside glucose to treat elevated blood potassium levels (hyperkalemia). While all types are commonly referred to as insulin, the term in its strictest sense applies to the naturally occurring molecule, whereas insulin analogues have modified structures to alter their pharmacokinetics. Certain insulin brands can also have differing names regionally, such as how Novolog is called Novorapid outside of the United States. Brands may also be commonly referred to with different names. For example, Basaglar, Abasaglar, and Abasria all refer to the same brand. Abasria is the brand's former name, while Basaglar and Abasaglar are regional. The three companies which produce the most insulin are Lilly, Novo Nordisk and Sanofi. These corporations control 99% of the global market by value and 96% by volume.
Sources: en.wikipedia.org
x = mass of adsorbate m = mass of adsorbent p = equilibrium pressure of the gaseous adsorbate in case of experiments made in the gas phase (gas/solid interaction with gaseous species/adsorbed species) K and n are constants for a given adsorbate and adsorbent at a given temperature (from there, the term isotherm needed to avoid significant gas pressure fluctuations due to uncontrolled temperature variations in the case of adsorption experiments of a gas onto a solid phase).
=== Replacement therapy === GH is used as replacement therapy in adults with GH deficiency of either childhood-onset or adult-onset (usually as a result of an acquired pituitary tumor). In these patients, benefits have variably included reduced fat mass, increased lean mass, increased bone density, improved lipid profile, reduced cardiovascular risk factors, and improved psychosocial well-being. Long acting growth hormone (LAGH) analogues are now available for treating growth hormone deficiency both in children and adults. These are once weekly injections as compared to conventional growth hormone which has to be taken as daily injections. LAGH injection 4 times a month has been found to be as safe and effective as daily growth hormone injections.
==== South Korea ==== In 1999 South Korea granted two patents to Pfizer related to sildenafil. The first document guaranteed sole production and sale of the substance until 2012, while the second gave Pfizer the exclusive use to treating erectile dysfunction with sildenafil until 2014. In 2011 Hanmi Pharmaceutical and CJ CheilJedang launched a suit against the exclusive use patent. The Korean Court system made a ruling against Pfizer in June 2012, allowing for the unhindered domestic production of generic prescription sildenafil. In 2012, Viagra lost its position as the top selling erectile dysfunction treatment in South Korea. This development was credited largely "due to the introduction of generic products." Generic sildenafil became publicly available in May. Sales of PalPal by Hanmi Pharmaceuticals totalled ₩22 billion or about 86% the market share of Viagra that year. By 2017, there were over 50 generic sildenafil pills available. During that year Viagra sales slumped to 38% that of Palpal.
Extraperitoneal fascia (also: endoabdominal fascia or subperitoneal fascia) is a fascial plane – consisting mostly of loose areolar connective tissue – situated between the fascial linings of the walls of the abdominal and pelvic cavities (transversalis fascia, anterior layer of thoracolumbar fascia, iliac fascia, and psoas fascia) externally, and the parietal peritoneum internally. Its quality and quantity varies considerably. It occupies the extraperitoneal space.
Lemna is a genus of free-floating aquatic plants referred to by the common name "duckweed". They are morphologically divergent members of the arum family Araceae. These rapidly growing plants have found uses as a model system for studies in community ecology, basic plant biology, ecotoxicology, and production of biopharmaceuticals, and as a source of animal feeds for agriculture and aquaculture. Currently, 14 species of Lemna are recognised.
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.